Abstract
Chronic pain patients taking narcotic pain medications were evaluated for the prevalence of genotypes linked with neurochemical deficiencies. They were genotyped using proprietary Proove Narcotic Risk Using Applied Biosystems RealTime PCR TaqMan assay on DRD1-48A>G, DRD2 A1 allele, DRD4-521C/T, DAT1 Ddel, COMT Val158Met, OPRK1 36G>T, OPRM1 A1 18G, DBH-1021C/T, 5-HT2A-1438G/A, 5-HTTLPR, GABA 1519T>C and MTHFR C677T. Subjects were chronic pain patients taking Rx narcotics (n=100). Statistical significance was found in the prevalence of DRD4-521C/T[79% v 29%](p<0.001), DAT1 Ddel[68% v 55%](p<0.05), COMT Val158met[74% v 47%](p<0.001), OPRK1 36G>T[16% v 3%](p<0.05) and OPRM1 A1 18G[17% v 47%](p<0.01). The prevalence of genetic predisposition to substance abuse among chronic pain patients taking prescription narcotic pain medications provides information to prescribers that may improve therapeutic decisions to avoid treatment failures and addiction. This study was supported by Proove Biosciences Inc.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
